Affibody Medical Investor Relations

Affibody regains worldwide rights to izokibep

News

February 2, 2025

Stockholm, Sweden, February 2, 2025. Affibody today announced that the company will regain all rights to izokibep.

In 2021, Affibody and ACELYRIN, INC. entered into a license and collaboration agreement granting ACELYRIN worldwide development and commercialization rights to izokibep, except in selected Asian countries. Following ACELYRIN’s previous announcement to halt internal development of izokibep the agreement will now be terminated. The termination will be effective after a three-month notice period after which all rights will revert, and the asset will be transferred to Affibody.

“At Affibody we are convinced that izokibep, with its clear path to approval and competitive profile, can become a game-changing drug in the dermatology field, particularly for the significant number of patients debilitated by HS,” said David Bejker, Chief Executive Officer of Affibody. “It is clear that ACELYRIN has not been able to fully capitalize on the potential demonstrated by izokibep’s best-in-class Phase 3 data.”